Εσθονία - Εσθονικά - Ravimiamet

gp-pharm s.a. - oktreotiid - süstelahus - 500mcg 1ml 1ml 5tk

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lümfoom, mantle-cell - antineoplastilised ained - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

tmc pharma (eu) limited - fosdenopterin hydrobromide dihydrate - metal metabolism, inborn errors - muud alimentary seedetrakti ja ainevahetust tooted, - nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (mocd) type a.

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemorraagilised ained - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

csl behring gmbh - inimeste koagulatsiooni faktor viii, inimese von willebrand faktori - hemophilia a; von willebrand diseases - blood coagulation factors, von willebrand factor and coagulation factor viii in combination, antihemorrhagics - von willebrand haigus (vwd)profülaktika ja ravi hemorraagia või kirurgilise verejooksu patsientidel vwd, kui desmopressin (ddavp) ravi üksi on ebaefektiivne või vastunäidustatud. hemofiilia (kaasasündinud tegur-viii puudulikkus)profülaktikaks ja raviks verejooksu patsientidel, kellel on hemofiilia a.

Εσθονία - Εσθονικά - Ravimiamet

medochemie limited - vorikonasool - õhukese polümeerikattega tablett - 50mg 50tk; 50mg 14tk; 50mg 28tk; 50mg 2tk; 50mg 30tk; 50mg 20tk; 50mg 56tk; 50mg 100tk

Εσθονία - Εσθονικά - Ravimiamet

medochemie limited - vorikonasool - õhukese polümeerikattega tablett - 200mg 10tk; 200mg 30tk; 200mg 50tk; 200mg 56tk; 200mg 28tk; 200mg 20tk; 200mg 100tk

Εσθονία - Εσθονικά - Ravimiamet

usolye-sibirsky chemical-pharmaceutical factory - ksantinoolnikotinaat - tablett - 150mg 60tk

Εσθονία - Εσθονικά - Ravimiamet

usolye-sibirsky chemical-pharmaceutical factory - tõrv+riitsinusõli+kseroform - salv - 3g+94g+3g 100g 30g 1tk

Εσθονία - Εσθονικά - Ravimiamet

usolye-sibirsky chemical-pharmaceutical factory - aminofülliin - tablett - 150mg 30tk